Axsome Therapeutics Inc
AXSM182.550USD
+1.710+0.95%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
9.18BMarket Cap
LossP/E TTM
More Details of Axsome Therapeutics Inc Company
Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
Axsome Therapeutics Inc Info
Ticker SymbolAXSM
Company nameAxsome Therapeutics Inc
IPO dateNov 19, 2015
CEOTabuteau (Herriot)
Number of employees683
Security typeOrdinary Share
Fiscal year-endNov 19
AddressOne World Trade Center, 29Th Floor
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10007
Phone12123323241
Websitehttps://www.axsome.com/
Ticker SymbolAXSM
IPO dateNov 19, 2015
CEOTabuteau (Herriot)
Company Executives of Axsome Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Independent Director
Independent Director
57.51K
-13464.00%
Mr. Nick Pizzie, CPA
Mr. Nick Pizzie, CPA
Chief Financial Officer
Chief Financial Officer
42.67K
--
Mr. Mark E. Saad
Mr. Mark E. Saad
Independent Director
Independent Director
10.30K
--
Dr. Herriot Tabuteau, M.D.
Dr. Herriot Tabuteau, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
7.23K
--
Mr. Mark L. Jacobson
Mr. Mark L. Jacobson
Chief Operating Officer
Chief Operating Officer
--
-5783.00%
Dr. Mark Coleman, M.D.
Dr. Mark Coleman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Hunter Murdock
Mr. Hunter Murdock
General Counsel
General Counsel
--
--
Dr. Susan M. (Sue) Mahony, Ph.D.
Dr. Susan M. (Sue) Mahony, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ari Maizel
Mr. Ari Maizel
Chief Commercial Officer
Chief Commercial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Independent Director
Independent Director
57.51K
-13464.00%
Mr. Nick Pizzie, CPA
Mr. Nick Pizzie, CPA
Chief Financial Officer
Chief Financial Officer
42.67K
--
Mr. Mark E. Saad
Mr. Mark E. Saad
Independent Director
Independent Director
10.30K
--
Dr. Herriot Tabuteau, M.D.
Dr. Herriot Tabuteau, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
7.23K
--
Mr. Mark L. Jacobson
Mr. Mark L. Jacobson
Chief Operating Officer
Chief Operating Officer
--
-5783.00%
Dr. Mark Coleman, M.D.
Dr. Mark Coleman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2023
FY2023Q4
FY2023Q3
By BusinessUSD
Name
Revenue
Proportion
Auvelitv
136.10M
79.60%
Sunosi
31.61M
18.49%
Symbravo
2.07M
1.21%
Sunosi royality revenue
1.21M
0.71%
By RegionUSD
Name
Revenue
Proportion
United States
169.18M
98.94%
Outside of the United States
1.82M
1.06%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Auvelitv
136.10M
79.60%
Sunosi
31.61M
18.49%
Symbravo
2.07M
1.21%
Sunosi royality revenue
1.21M
0.71%
Shareholding Stats
Updated: Sun, Jan 11
Updated: Sun, Jan 11
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Antecip Capital, L.L.C.
14.57%
The Vanguard Group, Inc.
8.24%
BlackRock Institutional Trust Company, N.A.
6.16%
Wellington Management Company, LLP
2.65%
RTW Investments L.P.
2.22%
Other
66.16%
Shareholders
Shareholders
Proportion
Antecip Capital, L.L.C.
14.57%
The Vanguard Group, Inc.
8.24%
BlackRock Institutional Trust Company, N.A.
6.16%
Wellington Management Company, LLP
2.65%
RTW Investments L.P.
2.22%
Other
66.16%
Shareholder Types
Shareholders
Proportion
Investment Advisor
36.67%
Investment Advisor/Hedge Fund
22.01%
Corporation
14.57%
Hedge Fund
11.48%
Research Firm
2.23%
Private Equity
1.35%
Individual Investor
1.13%
Pension Fund
1.09%
Sovereign Wealth Fund
0.93%
Other
8.54%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
643
38.50M
85.28%
+81.77K
2025Q3
657
38.45M
87.16%
-264.98K
2025Q2
636
38.74M
85.21%
+673.17K
2025Q1
604
38.08M
85.89%
-4.20M
2024Q4
561
37.78M
89.40%
-1.53M
2024Q3
529
39.25M
94.83%
-2.09M
2024Q2
515
41.51M
92.29%
+1.90M
2024Q1
502
39.61M
93.44%
-4.74M
2023Q4
476
39.34M
91.45%
+441.54K
2023Q3
467
38.94M
87.84%
+1.52M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Antecip Capital, L.L.C.
7.34M
14.57%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
4.17M
8.28%
+235.15K
+5.97%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.10M
6.16%
-38.55K
-1.23%
Sep 30, 2025
Wellington Management Company, LLP
1.33M
2.65%
+609.52K
+84.07%
Sep 30, 2025
RTW Investments L.P.
1.12M
2.22%
-398.02K
-26.24%
Sep 30, 2025
Nomura Investment Management Business Trust
1.08M
2.15%
-53.21K
-4.68%
Sep 30, 2025
Geode Capital Management, L.L.C.
997.70K
1.98%
+8.25K
+0.83%
Sep 30, 2025
T. Rowe Price Associates, Inc.
994.50K
1.97%
+418.57K
+72.68%
Sep 30, 2025
Invesco Advisers, Inc.
949.36K
1.88%
+420.83K
+79.62%
Sep 30, 2025
State Street Investment Management (US)
942.96K
1.87%
-15.54K
-1.62%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
4.69%
ALPS Medical Breakthroughs ETF
2.85%
State Street SPDR S&P Pharmaceuticals ETF
2.84%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.73%
iShares U.S. Pharmaceuticals ETF
2.09%
Virtus LifeSci Biotech Products ETF
2.03%
ProShares Ultra Nasdaq Biotechnology
0.92%
iShares Health Innovation Active ETF
0.89%
JPMorgan Healthcare Leaders ETF
0.8%
VanEck Pharmaceutical ETF
0.75%
View more
iShares Neuroscience and Healthcare ETF
Proportion4.69%
ALPS Medical Breakthroughs ETF
Proportion2.85%
State Street SPDR S&P Pharmaceuticals ETF
Proportion2.84%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion2.73%
iShares U.S. Pharmaceuticals ETF
Proportion2.09%
Virtus LifeSci Biotech Products ETF
Proportion2.03%
ProShares Ultra Nasdaq Biotechnology
Proportion0.92%
iShares Health Innovation Active ETF
Proportion0.89%
JPMorgan Healthcare Leaders ETF
Proportion0.8%
VanEck Pharmaceutical ETF
Proportion0.75%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
